Antimicrobial Susceptibility Testing in Secondary Viral Co-infections: Principles, Methods, and Clinical Integration

Introduction

Secondary bacterial infections frequently complicate primary viral diseases in veterinary patients, leading to increased morbidity, prolonged clinical courses, and higher mortality rates [1]. The selection of appropriate antimicrobial therapy for these secondary infections requires accurate identification of the bacterial pathogen and determination of its susceptibility to available antimicrobial agents. Antimicrobial susceptibility testing (AST) provides the laboratory evidence necessary to guide empirical and targeted therapy, reduce the selection pressure for resistance, and improve clinical outcomes [2]. This article reviews the principles, methods, and clinical integration of AST specifically in the context of secondary viral co-infections in animals, with emphasis on the unique challenges posed by the underlying viral disease.

Biological Basis of Secondary Bacterial Infections Following Viral Disease

Viral infections predispose the host to bacterial superinfection through multiple mechanisms. Epithelial damage caused by viral replication exposes basement membrane receptors and disrupts mucociliary clearance, facilitating bacterial adherence and invasion [3]. Immunomodulation induced by viruses, including suppression of phagocyte function and altered cytokine profiles, further compromises host defenses [4]. Common veterinary examples include secondary bacterial pneumonia following infection with Canine Distemper Virus or Canine Influenza Virus, and secondary enteritis after Canine Parvovirus infection [1, 5]. In poultry, secondary bacterial infections often follow Highly Pathogenic Avian Influenza (H5N1) or Newcastle Disease Virus infection, with Escherichia coli and Ornithobacterium rhinotracheale being common isolates [6]. In swine, Porcine Reproductive and Respiratory Syndrome Virus infection predisposes to secondary bacterial pneumonia caused by Mycoplasma hyopneumoniae, Pasteurella multocida, and Streptococcus suis [7].

Principles of Antimicrobial Susceptibility Testing

AST measures the in vitro activity of an antimicrobial agent against a specific bacterial isolate. The fundamental principle involves exposing a standardized inoculum of the bacterium to defined concentrations of the antimicrobial and observing growth inhibition [2]. Results are expressed as the minimum inhibitory concentration (MIC) or as a categorical interpretation (susceptible, intermediate, resistant) based on clinical breakpoints [8]. Clinical breakpoints are established by regulatory bodies such as the Clinical and Laboratory Standards Institute (CLSI) and are species-specific, site-specific, and pathogen-specific [9]. For veterinary medicine, CLSI documents VET01 through VET09 provide standardized methods and interpretive criteria for animal pathogens [9].

The selection of antimicrobials to test should be guided by the bacterial species isolated, the site of infection, the pharmacokinetic and pharmacodynamic properties of the drug in the target animal species, and local resistance patterns [10]. In the context of secondary viral co-infections, the underlying viral disease may alter drug distribution, metabolism, or excretion, potentially affecting the correlation between in vitro susceptibility and in vivo efficacy [11]. Therefore, AST results must be interpreted with caution, and clinical response should be monitored closely.

Phenotypic Methods for AST

Disk Diffusion (Kirby-Bauer) Method

The disk diffusion method is a simple, cost-effective technique suitable for rapidly growing aerobic and facultative anaerobic bacteria [2]. A standardized bacterial suspension (equivalent to a 0.5 McFarland standard) is inoculated onto Mueller-Hinton agar, and filter paper disks impregnated with defined concentrations of antimicrobial agents are placed on the surface [12]. After incubation at 35 degrees Celsius for 16 to 24 hours, zones of inhibition are measured and compared to CLSI breakpoint tables [9]. The method is widely used in veterinary diagnostic laboratories for routine isolates from secondary infections, such as E. coli from post-viral pneumonia or Staphylococcus pseudintermedius from secondary pyoderma following viral dermatitis [13]. Limitations include the inability to provide an exact MIC and reduced reliability for slow-growing or fastidious organisms [2].

Broth Microdilution Method

Broth microdilution is the reference method for MIC determination and is recommended for fastidious bacteria and for isolates from serious infections [2]. Serial two-fold dilutions of antimicrobial agents are prepared in 96-well microtiter plates containing Mueller-Hinton broth, and a standardized bacterial inoculum is added [14]. After incubation, the MIC is read as the lowest concentration that inhibits visible growth. Commercial dehydrated panels are available for veterinary pathogens and include antimicrobials relevant to companion animal and livestock medicine [15]. This method is particularly useful for secondary infections in which precise MIC data are needed to guide dose optimization, such as in cases of post-viral pneumonia in foals or calves [16].

Agar Dilution Method

Agar dilution involves incorporating antimicrobial agents at various concentrations into agar plates, which are then inoculated with a standardized bacterial suspension [2]. This method is primarily used for research and for testing multiple isolates simultaneously. It is less commonly employed in routine veterinary diagnostics due to its labor-intensive nature [17].

Gradient Diffusion Method

Gradient diffusion (e.g., Etest) uses a plastic strip impregnated with a continuous gradient of antimicrobial concentrations [18]. When placed on an inoculated agar plate, an elliptical zone of inhibition forms, and the MIC is read at the intersection of the zone edge with the strip. This method provides a direct MIC and is useful for individual isolates or when broth microdilution is not available [18]. It is often employed for fastidious organisms such as Streptococcus equi subsp. zooepidemicus isolated from secondary infections in horses following viral respiratory disease [19].

Genotypic Methods for Resistance Detection

Genotypic methods detect specific resistance genes or mutations directly from bacterial isolates or clinical samples [20]. These methods are increasingly integrated into veterinary diagnostics, especially for secondary infections where rapid results are critical.

Polymerase Chain Reaction (PCR) and Real-Time PCR

Conventional and real-time PCR assays target genes encoding resistance mechanisms, such as beta-lactamases (e.g., blaCTX-M, blaTEM, blaSHV), methicillin resistance (mecA in staphylococci), and vancomycin resistance (vanA, vanB in enterococci) [21]. Multiplex PCR panels can simultaneously detect multiple resistance determinants. For example, in secondary bacterial pneumonia following viral infection in swine, PCR can rapidly identify mecA-positive Staphylococcus aureus or extended-spectrum beta-lactamase (ESBL)-producing E. coli [22]. The advantage of PCR is speed; results can be obtained within hours, whereas phenotypic AST requires 16 to 48 hours [20]. However, PCR detects the genetic potential for resistance, not its phenotypic expression, and may miss novel or uncharacterized resistance mechanisms [23].

Whole-Genome Sequencing (WGS)

WGS provides comprehensive information on the entire resistance gene repertoire (resistome) of a bacterial isolate [24]. Bioinformatics pipelines identify known resistance genes and mutations in chromosomal targets (e.g., gyrase and topoisomerase genes for fluoroquinolone resistance) [25]. WGS is increasingly used in veterinary reference laboratories for outbreak investigations and surveillance of antimicrobial resistance in secondary infections [26]. The cost and turnaround time have decreased, making WGS feasible for selected clinical cases, particularly in livestock operations where multidrug-resistant pathogens are common [27]. However, WGS still requires bioinformatics expertise and is not yet a routine point-of-care tool [24].

Microarray-Based Methods

Commercial microarrays can detect hundreds of resistance genes simultaneously from a bacterial isolate or directly from clinical samples [28]. These arrays are used in veterinary research and some diagnostic laboratories for comprehensive resistance profiling of secondary pathogens [29]. They offer a middle ground between targeted PCR and WGS in terms of throughput and cost.

Clinical Integration of AST in Secondary Viral Co-infections

Sample Collection and Timing

Appropriate sample collection is critical for accurate AST. Samples should be obtained from the site of infection before antimicrobial therapy is initiated [30]. In animals with viral respiratory disease, bronchoalveolar lavage, transtracheal wash, or nasal swabs can be submitted for bacterial culture and AST [31]. For secondary enteritis, fecal samples or rectal swabs are appropriate. The timing of collection relative to the onset of viral signs is important; bacterial superinfection typically occurs 3 to 7 days after viral infection [1]. Repeated sampling may be necessary if initial cultures are negative but clinical suspicion remains high.

Interpretation of AST Results in the Context of Viral Infection

The presence of a concurrent viral infection can influence the interpretation of AST results. Viral-induced inflammation may alter the pharmacokinetics of antimicrobial agents, leading to lower tissue concentrations than predicted [11]. Additionally, the immune status of the host is compromised, so bacteriostatic agents may be less effective than bactericidal agents [32]. Therefore, when selecting therapy for secondary infections, preference is often given to bactericidal drugs with a wide therapeutic index [33]. The clinical breakpoints used for interpretation are derived from studies in healthy animals; their applicability in virally compromised patients is not fully validated [9]. Clinicians should consider using the highest recommended dose within the labeled range and monitor for adverse effects.

Empirical Therapy While Awaiting AST Results

In many secondary viral co-infections, empirical antimicrobial therapy is initiated before AST results are available [34]. The choice of empirical agent should be based on the most likely bacterial pathogens, local resistance patterns, and the severity of the clinical condition. For example, in post-viral pneumonia in dogs, empirical coverage for Bordetella bronchiseptica, Streptococcus equi subsp. zooepidemicus, and Mycoplasma cynos may be indicated [35]. In poultry, after an outbreak of avian influenza, empirical therapy for secondary E. coli infection often includes amoxicillin or tetracyclines, but resistance is common, necessitating AST-guided therapy [6]. Once AST results are available, therapy should be de-escalated to the narrowest spectrum agent with proven susceptibility [36].

Monitoring and Follow-Up

Clinical response should be reassessed 48 to 72 hours after initiation of therapy [37]. If there is no improvement, AST results should be reviewed, and the antimicrobial regimen adjusted accordingly. Repeat culture and AST may be indicated if the initial isolate was not representative or if a new pathogen has emerged [38]. In cases of treatment failure despite in vitro susceptibility, consideration should be given to biofilm formation, poor drug penetration, or the presence of a mixed infection [39].

Decision Tree for AST in Secondary Viral Co-infections

The following Mermaid diagram outlines a clinical decision tree for integrating AST into the management of secondary bacterial infections following viral disease.

flowchart TD
 A[Clinical signs of secondary bacterial infection post-viral disease] --> B{Collect appropriate sample}
 B --> C[Gram stain and culture]
 C --> D{Significant bacterial growth?}
 D -- Yes --> E["Perform AST: disk diffusion or MIC method"]
 D -- No --> F[Consider viral etiology or non-infectious cause]
 E --> G[Interpret AST using veterinary breakpoints]
 G --> H{Select antimicrobial therapy}
 H --> I[Initiate empirical therapy if not already started]
 I --> J[Reassess at 48-72 hours]
 J --> K{Clinical improvement?}
 K -- Yes --> L["Continue therapy; complete course"]
 K -- No --> M["Review AST; consider resistance, dosing, or mixed infection"]
 M --> N[Adjust therapy based on AST and PK/PD]
 N --> J

Challenges and Limitations

Several challenges complicate AST in secondary viral co-infections. First, the bacterial pathogen may be present in low numbers or may be overgrown by commensal flora, leading to false-negative cultures [40]. Second, the viral infection itself may cause cytopathic effects that interfere with bacterial isolation [41]. Third, antimicrobial resistance is more prevalent in isolates from animals with prior antimicrobial exposure, which is common in secondary infections [42]. Fourth, the lack of validated clinical breakpoints for many veterinary pathogens and host species limits the interpretability of AST results [9]. Finally, genotypic methods may detect resistance genes that are not expressed or are present in a minority of the bacterial population, leading to discordance with phenotypic results [23].

Future Directions

Advances in rapid AST technologies, such as flow cytometry-based detection of bacterial viability after short exposure to antimicrobials, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for direct detection of resistance mechanisms, hold promise for reducing turnaround times [43]. Integration of AST data with electronic medical records and antimicrobial stewardship programs can improve prescribing practices and reduce the emergence of resistance [44]. In veterinary medicine, the development of species-specific and disease-specific clinical breakpoints remains a priority [9].

Conclusion

Antimicrobial susceptibility testing is an essential tool for managing secondary bacterial infections that complicate viral diseases in animals. Phenotypic methods, including disk diffusion and broth microdilution, remain the standard for routine diagnostics, while genotypic methods offer rapid detection of resistance determinants. Clinical integration of AST requires careful sample collection, interpretation of results in the context of the viral infection, and timely adjustment of therapy. Despite challenges, AST-guided therapy improves clinical outcomes and supports antimicrobial stewardship in veterinary practice.

References

[1] Greene CE. Infectious Diseases of the Dog and Cat. 4th ed. St. Louis: Elsevier Saunders; 2012.

[2] Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals. 5th ed. CLSI document VET01. Wayne, PA: CLSI; 2020.

[3] McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev. 2006;19(3):571-582.

[4] Didierlaurent A, Goulding J, Hussell T. The impact of successive infections on the lung microenvironment. Immunology. 2007;122(4):457-465.

[5] Macartney L, McCandlish IA, Thompson H, Cornwell HJC. Canine parvovirus enteritis 1: clinical, haematological and pathological features of experimental infection. Vet Rec. 1984;115(9):201-210.

[6] Swayne DE, Glisson JR, McDougald LR, Nolan LK, Suarez DL, Nair V, editors. Diseases of Poultry. 14th ed. Ames: Wiley-Blackwell; 2020.

[7] Zimmerman JJ, Karriker LA, Ramirez A, Schwartz KJ, Stevenson GW, Zhang J, editors. Diseases of Swine. 11th ed. Hoboken: Wiley-Blackwell; 2019.

[8] Turnidge JD, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev. 2007;20(3):391-408.

[9] Clinical and Laboratory Standards Institute. Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters for Veterinary Antimicrobial Agents. 4th ed. CLSI document VET02. Wayne, PA: CLSI; 2019.

[10] Papich MG. Antimicrobial agent use in small animals. In: Giguère S, Prescott JF, Dowling PM, editors. Antimicrobial Therapy in Veterinary Medicine. 5th ed. Ames: Wiley-Blackwell; 2013. p. 437-454.

[11] Martinez M, Toutain PL, Turnidge J. The pharmacodynamics of antimicrobial agents. In: Giguère S, Prescott JF, Dowling PM, editors. Antimicrobial Therapy in Veterinary Medicine. 5th ed. Ames: Wiley-Blackwell; 2013. p. 79-104.

[12] Bauer AW, Kirby WMM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966;45(4):493-496.

[13] Bannoehr J, Guardabassi L. Staphylococcus pseudintermedius in the dog: taxonomy, diagnostics, ecology, epidemiology and pathogenicity. Vet Dermatol. 2012;23(4):253-266.

[14] Jorgensen JH, Turnidge JD. Susceptibility test methods: dilution and disk diffusion methods. In: Jorgensen JH, Pfaller MA, Carroll KC, et al., editors. Manual of Clinical Microbiology. 11th ed. Washington, DC: ASM Press; 2015. p. 1253-1273.

[15] Lubbers BV, Schrafel L, Hanzlicek GA, et al. Antimicrobial susceptibility patterns of Escherichia coli isolated from clinical cases of bovine respiratory disease complex in the United States. J Vet Diagn Invest. 2011;23(5):1001-1004.

[16] Giguère S, Prescott JF. Antimicrobial therapy in horses. In: Giguère S, Prescott JF, Dowling PM, editors. Antimicrobial Therapy in Veterinary Medicine. 5th ed. Ames: Wiley-Blackwell; 2013. p. 455-474.

[17] Wiegand I, Hilpert K, Hancock REW. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc. 2008;3(2):163-175.

[18] Baker CN, Stocker SA, Culver DH, Thornsberry C. Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J Clin Microbiol. 1991;29(3):533-538.

[19] Timoney JF. The pathogenic equine streptococci. Vet Res. 2004;35(4):397-409.

[20] Fluit AC, Visser MR, Schmitz FJ. Molecular detection of antimicrobial resistance. Clin Microbiol Rev. 2001;14(4):836-871.

[21] Dalleme C, Da Costa A, Decré D, Favier C, Arlet G. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. J Antimicrob Chemother. 2010;65(3):490-495.

[22] Aarestrup FM, Wegener HC, Collignon P. Resistance in bacteria of the food chain: epidemiology and control strategies. Expert Rev Anti Infect Ther. 2008;6(5):733-750.

[23] Courvalin P. Genotypic and phenotypic detection of antimicrobial resistance. In: Mayers DL, editor. Antimicrobial Drug Resistance. 2nd ed. Cham: Springer; 2017. p. 85-98.

[24] Köser CU, Ellington MJ, Peacock SJ. Whole-genome sequencing to control antimicrobial resistance. Trends Genet. 2014;30(9):401-407.

[25] Zankari E, Hasman H, Cosentino S, et al. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother. 2012;67(11):2640-2644.

[26] Mather AE, Reid SWJ, Maskell DJ, et al. Distinguishable epidemics of multidrug-resistant Salmonella Typhimurium DT104 in different hosts. Science. 2013;341(6153):1514-1517.

[27] Anjum MF, Zankari E, Hasman H. Identification of acquired antimicrobial resistance genes. Methods Mol Biol. 2017;1520:57-73.

[28] Frye JG, Lindsey RL, Meinersmann RJ, et al. Development of a DNA microarray for detection of antimicrobial resistance genes in bacteria. J Antimicrob Chemother. 2006;57(6):1045-1055.

[29] Batchelor M, Hopkins KL, Liebana E, et al. Development of a microarray for detection of antimicrobial resistance genes in Salmonella. J Antimicrob Chemother. 2008;62(1):73-78.

[30] Baron EJ, Miller JM, Weinstein MP, et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clin Infect Dis. 2013;57(4):e22-e121.

[31] Hawkins EC. Bronchoalveolar lavage. In: King LG, editor. Textbook of Respiratory Disease in Dogs and Cats. St. Louis: Elsevier Saunders; 2004. p. 118-128.

[32] Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis. 2004;38(6):864-870.

[33] Dowling PM. Antimicrobial therapy of the respiratory tract. In: Giguère S, Prescott JF, Dowling PM, editors. Antimicrobial Therapy in Veterinary Medicine. 5th ed. Ames: Wiley-Blackwell; 2013. p. 341-358.

[34] Weese JS. Antimicrobial use in companion animals. Anim Health Res Rev. 2008;9(2):127-133.

[35] Priestnall SL, Mitchell JA, Walker CA, et al. New and emerging pathogens in canine infectious respiratory disease complex. Vet Clin North Am Small Anim Pract. 2014;44(2):241-256.

[36] Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159-177.

[37] Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013;13(12):1057-1098.

[38] Dohoo I, Martin W, Stryhn H. Veterinary Epidemiologic Research. 2nd ed. Charlottetown: VER Inc.; 2009.

[39] Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15(2):167-193.

[40] Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, editors. Manual of Clinical Microbiology. 9th ed. Washington, DC: ASM Press; 2007.

[41] Fenner F, Bachmann PA, Gibbs EPJ, et al. Veterinary Virology. 2nd ed. San Diego: Academic Press; 1993.

[42] Guardabassi L, Schwarz S, Lloyd DH. Pet animals as reservoirs of antimicrobial-resistant bacteria. J Antimicrob Chemother. 2004;54(2):321-332.

[43] van Belkum A, Dunne WM. Next-generation antimicrobial susceptibility testing. J Clin Microbiol. 2013;51(7):2018-2024.

[44] Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51-e77. *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.